Comorbidity as a factor of prognosis in patients with locoregionally advanced, inoperable squamocellular head and neck cancers
Abstract
Background/Aim. Patients (pts) with tumors often have other diseases or conditions in addition to their index cancer which are generally referred to as comorbidities. Due to the fact that well known risk factors for development of squamocellular head and neck cancers (HNSCC) such as tobacco and alcohol abuse can also damage other important organs, pts with this type of cancer are suitable for analyzing the influence of comorbid conditions on prognosis of the disease. The aim of our work was to assess the prevalence of comorbidities, most frequent conditions and their prognostic impact on overall survival in this particular population. Methods. Between July 2002 and January 2007 in the Institute for Oncology and Radiology of Serbia, 100 pts with locoregionally advanced, inoperable HNSCC were initially treated with neoadjuvant chemotherapy regimen, cytarabine-5 fluorouracil-cisplatinum. Median age of pts was 55 years, most of them (91%) were males with median number of applied chemo cycles being 4. Data on comorbidities were collected in prospective manner from various sources prior to the treatment. For grading of the severity of comorbid conditions, the Adult Comorbidity Evaluation 27 (ACE-27) comorbidity index was used with four degree scale (0–3). The average follow-up of pts was 15 months with range from 3–59 months. Results. Comorbidities were present in 69 (69%) pts, and 31 (39%) pts had no comorbidities prior to the treatment. Among pts with comorbid conditions prevailed alcoholics, active and former (71%), pts with chronic lung diseases (25%) and cardiovascular diseases (18%). Overall comorbidity score was defined according to the highest ranked single ailment, except in the case where two or more grade 2 ailments occured in different organ systems in which case the overall comorbidity score was designated as grade 3. Median overall survival for the whole group was 12 months. Median ACE-27 score was grade 1 (range 0–3) which was observed in 43 (43%) pts. Pts without comorbidities survived significantly longer than those with any kind of comorbidity (p = 0.0089), and the same was observed comparing survival of pts without comorbidities and those with comorbidity index 2 and 3 taken together (p = 0.0047). Results of other intergroup comparisons were of no statistic significance. Conclusion. Comorbidity is important prognostic variable in patients with locoregionally advanced HNSCC and should be properly assessed prior to therapy.
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66(1): 7–30.
Naghavi M. The Global Burden of Cancer 2013. JAMA Oncol 2015; 1(4): 505–27.
Hospital registry for cancer. Belgrade: Institute of Oncology and Radiology of Serbia; 2010.
Haddad RI, Shin DM. Recent advanced in head and neck can-cer. N Engl J Med 2008; 359(11): 1143–54.
Piccirillo JF. Importance of comorbidity in head and neck can-cer. Laryngoscope 2000; 110(4): 593–602.
Feinstein AR. The pre-therapeutic classification of co-morbidity in chronicdisease. J Chronic Dis 1970; 23(7): 455–68.
Fine JP, Gray RJ. A proportional hazards model for the subdis-tribution of a competing risk. J Am Stat Assoc 1999; 94(446): 496–509.
Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974; 27(7–8): 387–404.
Mukherjee B, Ou HT, Wang F, Erickson SR. A new comorbidity index: the health-related quality of life comorbidity index. J Clin Epidemiol 2011; 64(3): 309–19.
Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based can-cer registry. JAMA 2004; 291(20): 2441–7.
Piccirillo JF, Vlahiotis A. Comorbidity in patients with cancer of the head and neck: prevalence and impact on treatment and prognosis. Curr Oncol Rep 2006; 8(2): 123–9.
Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011; 29(10): 1335–41.
Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol 2012; 41(3): 861–70.
Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380(9836): 37–43.
Hall SF, Rochon PA, Streiner DL, Paszat LF, Groome PA, Rohland SL. Measuring comorbidity in patients with head and neck cancer. Laryngoscope 2002; 112(11): 1988–96.
Datema FR, Ferrier MB, van der Schroeff MP, Baatenburg de Jong RJ. Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck 2010; 32(6): 728–36.
Land LH, Dalton SO, Jensen MB, Ewertz M. Impact of comor-bidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990-2008. Breast Cancer Res Treat 2012; 131(3): 1013–20.
Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst 2011; 103(14): 1101–11.